Ponatinib may make allogeneic hematopoietic stem cell transplantation unnecessary for CML-BC under specific conditions, such as de novo cases: a case series of de novo CML-BC treated with ponatinib and no transplantation
Leuk Lymphoma. 2025 Nov;66(11):2143-2146.
doi: 10.1080/10428194.2025.2521646.
Epub 2025 Jun 25.